Quoin Pharmaceuticals (QNRX) Price & Analysis

Q: What was Quoin Pharmaceuticals’s price range in the past 12 months?

Quoin Pharmaceuticals lowest stock price was $5.01 and its highest was $41.80 in the past 12 months.

Q: What is Quoin Pharmaceuticals’s market cap?

Quoin Pharmaceuticals’s market cap is $4.94M.

Q: When is Quoin Pharmaceuticals’s upcoming earnings report date?

Quoin Pharmaceuticals’s upcoming earnings report date is Mar 12, 2026 which is in 23 days.

Q: How were Quoin Pharmaceuticals’s earnings last quarter?

Quoin Pharmaceuticals released its earnings results on Nov 06, 2025. The company reported -$6.71 earnings per share for the quarter, missing the consensus estimate of -$4.285 by -$2.425.

Q: Is Quoin Pharmaceuticals overvalued?

According to Wall Street analysts Quoin Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Quoin Pharmaceuticals pay dividends?

Quoin Pharmaceuticals does not currently pay dividends.

Q: What is Quoin Pharmaceuticals’s EPS estimate?

Quoin Pharmaceuticals’s EPS estimate is -4.02.

Q: How many shares outstanding does Quoin Pharmaceuticals have?

Quoin Pharmaceuticals has 838,977 shares outstanding.

Q: What happened to Quoin Pharmaceuticals’s price movement after its last earnings report?

Quoin Pharmaceuticals reported an EPS of -$6.71 in its last earnings report, missing expectations of -$4.285. Following the earnings report the stock price went down -11.192%.

Q: Which hedge fund is a major shareholder of Quoin Pharmaceuticals?

Currently, no hedge funds are holding shares in QNRX

Compare

371 Followers

QNRX Stock Chart & Stats

$11.72

-$0.04(-5.59%)

At close: Jan 08 4:00 PM EST

$11.72

-$0.04(-5.59%)

Day’s Range― - ―

52-Week Range$5.01 - $41.80

Previous CloseN/A

Volume155.80K

Average Volume (3M)629.04K

Market Cap

$4.94M

Enterprise Value$3.11M

Total Cash (Recent Filing)$5.41M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta-1.14

Next Earnings

Mar 12, 2026

EPS Estimate

-4.02

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-6.71

Shares Outstanding838,977

10 Day Avg. Volume1,633,105

30 Day Avg. Volume629,040

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)0.33

Price to Sales (P/S)0.00

P/FCF Ratio-0.39

Enterprise Value/Market Cap0.63

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-0.22

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Awareness Campaign SuccessThe success of the NETHERTON NOW campaign enhances Quoin's visibility and credibility in addressing rare diseases, potentially aiding future product acceptance and partnerships.

Leadership StrengthThe appointment of an experienced CFO strengthens Quoin's financial leadership, which is crucial for navigating commercialization and financial challenges.

Product Pipeline ProgressProgress in clinical studies for QRX003 indicates potential for future revenue generation and market entry, critical for long-term growth.

Bears Say

Financial InstabilityThe lack of revenue and reliance on external financing highlight financial instability, posing risks to operational sustainability and growth.

Negative Cash FlowPersistent negative cash flow and dependence on external funding raise concerns about Quoin's ability to sustain operations without new revenue streams.

Lack Of ProfitabilityThe absence of revenue and profitability underscores significant challenges in achieving financial stability, impacting long-term viability.

Quoin Pharmaceuticals News

Quoin announces submission to Japanese MHLW for ODD for QRX003

Quoin Pharmaceuticals (QNRX) announced that following a successful meeting with the Japanese MHLW that it has submitted an...

20d ago

QNRX

Quoin files Breakthrough Medicine Designation with SFDA for QRX003

Quoin Pharmaceuticals (QNRX) announced that it has filed an application for Breakthrough Medicine Designation with the Saudi Food...

27d ago

QNRX

Quoin seeks Saudi breakthrough status for Netherton therapy

The latest update is out from Quoin Pharmaceuticals ( ($QNRX) ). On January 20, 2026, Quoin Pharmaceuticals announced...

27d ago

QNRX

Quoin Pharmaceuticals Approves New Stock Option Agreements

Quoin Pharmaceuticals ( ($QNRX) ) has shared an update. On November 14, 2025, Quoin Pharmaceuticals‘ Board of Directors...

3M ago

QNRX

Promising Prospects for Quoin Pharmaceuticals: Buy Rating Backed by Innovative Developments and Pipeline Diversification

Naz Rahman, an analyst from Maxim Group, reiterated the Buy rating on Quoin Pharmaceuticals. The associated price target...

3M ago

QNRX

Quoin Pharmaceuticals Achieves Key Milestone in Rapamycin Delivery

Quoin Pharmaceuticals ( ($QNRX) ) just unveiled an update. On November 11, 2025, Quoin Pharmaceuticals announced the successful...

3M ago

QNRX

Quoin announces achievement of rapamycin target loadings

Quoin Pharmaceuticals (QNRX) announced that the target loading concentrations for its two topical rapamycin delivery technologies have been...

3M ago

QNRX

Quoin Pharmaceuticals Reports Q3 2025 Financial Results

Quoin Pharmaceuticals Ltd ( ($QNRX) ) has released its Q3 earnings. Here is a breakdown of the information...

3M ago

QNRX

Quoin Pharmaceuticals files to sell 10.05M ADSs for holders

16:50 EST Quoin Pharmaceuticals (QNRX) files to sell 10.05M ADSs for holders Published first on TheFly – the...

3M ago

QNRX

Promising Outlook for Quoin Pharmaceuticals: Buy Rating Backed by Strong Financial Position and Positive QRX003 Data

Analyst Naz Rahman of Maxim Group reiterated a Buy rating on Quoin Pharmaceuticals, retaining the price target of...

3M ago

QNRX

Quoin Pharmaceuticals reports Q3 EPS ($6.71) vs. ($16.29) last year

“The third quarter of 2025 has been a period of significant momentum and strategic advancement for Quoin Pharmaceuticals...

3M ago

QNRX

Quoin Pharmaceuticals sees cash runway into 2027

Quoin had approximately $5.4 million in cash, cash equivalents, and marketable securities as of September 30, 2025. The...

3M ago

QNRX

Quoin recruits three additional patients to Netherton Syndrome study

Quoin Pharmaceuticals (QNRX) announces recruitment of three additional patients in its investigator led pediatric Netherton Syndrome study as...

4M ago

QNRX

Quoin Pharmaceuticals Advances in Netherton Syndrome Treatment Study

Quoin Pharmaceuticals Ltd (($QNRX)) announced an update on their ongoing clinical study. Quoin Pharmaceuticals Ltd is conducting a...

4M ago

QNRX

QNRX FAQ

What was Quoin Pharmaceuticals’s price range in the past 12 months?

Quoin Pharmaceuticals lowest stock price was $5.01 and its highest was $41.80 in the past 12 months.

What is Quoin Pharmaceuticals’s market cap?

Quoin Pharmaceuticals’s market cap is $4.94M.

When is Quoin Pharmaceuticals’s upcoming earnings report date?

Quoin Pharmaceuticals’s upcoming earnings report date is Mar 12, 2026 which is in 23 days.

How were Quoin Pharmaceuticals’s earnings last quarter?

Quoin Pharmaceuticals released its earnings results on Nov 06, 2025. The company reported -$6.71 earnings per share for the quarter, missing the consensus estimate of -$4.285 by -$2.425.

Is Quoin Pharmaceuticals overvalued?

According to Wall Street analysts Quoin Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Quoin Pharmaceuticals pay dividends?

Quoin Pharmaceuticals does not currently pay dividends.

What is Quoin Pharmaceuticals’s EPS estimate?

Quoin Pharmaceuticals’s EPS estimate is -4.02.

How many shares outstanding does Quoin Pharmaceuticals have?

Quoin Pharmaceuticals has 838,977 shares outstanding.

What happened to Quoin Pharmaceuticals’s price movement after its last earnings report?

Quoin Pharmaceuticals reported an EPS of -$6.71 in its last earnings report, missing expectations of -$4.285. Following the earnings report the stock price went down -11.192%.

Which hedge fund is a major shareholder of Quoin Pharmaceuticals?

Currently, no hedge funds are holding shares in QNRX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.